Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702]

Affiliations

• ¹ Centro de Investigación, Clínica Bradford Hill, Santiago, Chile. Electronic address: [email protected].
• ² Latvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia.
• ³ Department of Antitumor Drug Therapy, MEDSI Clinical Hospital, Moscow, Russia.
• ⁴ Faculty of Medicine, Vajira Hospital, Bangkok Metropolitan University, Bangkok, Thailand.
• ⁵ Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ⁶ Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.
• ⁷ Product Safety Development, Genentech, Inc., South San Francisco, CA, USA.
• ⁸ Data and Statistical Sciences, Genentech, Inc., South San Francisco, CA, USA.
• ⁹ Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ¹⁰ BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA.
• ¹¹ Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Clinical Research Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.